Pathologist, Clinical Associate Professor, Pathology, University of Calgary, Calgary, AB
Dr. Bismar is currently an associate professor at the University of Calgary and Adjunct Professor in the Department of Oncology at McGill University. His most significant service achievement while at McGill University was the establishment and participation of urological oncology week rounds at JGH, besides being the primary and one of the consultative pathologists for signing out GU oncology cases. In 2012, Dr. Bismar was awarded the Donald Coffey Prize (BJ U lnt) winner for Best Research Paper of PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Dr. Bismar’s research achievements include the establishment and directorship of the tissue microarray (TMA) facility at the Lady Davis Institute with the support of Dr. Gerald Batist. This facility was an important step in the support of various investigators research projects pertaining to tissue sectioning, TMA construction and immunohistochemistry. Moreover, Dr. Bismar’s accomplishments also include the establishment of several TMAs for prostate cancer with detailed clinical and pathological outcome, which are currently being utilized in carious collaborative projects with several investigators. These collaborations have and continue to be an important part of numerous high impact journal publications and grant submissions. Dr. Bismar’s research accomplishments include the recent characterization of a 10 gene model with prognostic implications in prostate, breast and leukemia, which are currently being validated for potential clinical implementation.
Relevant Publications
Box A, Alshalalfa M, Hegazy SA, Donnelly B, Bismar TA*. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer. Tumour Biol. 2016 Sep;37(9):12287-12299. Epub 2016 Jun 7. PMID: 27271990
Huang KC, Evans A, Donnelly B, Bismar TA*. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion. Pathol Oncol Res. 2017 Apr;23(2):399-407. doi: 10.1007/s12253-016-0119-9. Epub 2016 Oct 13. PMID: 27738792
Wang T, Abou-Ouf H, Hegazy SA, Alshalalfa M, Stoletov K, Lewis J, Donnelly B, Bismar TA*. Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients. J Mol Med (Berl). 2016 Dec;94(12):1411-1422. Epub 2016 Aug 18. PMID: 27534968
Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K, Alaoui-Jamali MA, Bismar TA*. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. Mod Biol Rep. 2016 Apr;43(4):229-40.Epub 2016 Feb 23
Almami A, Hegazy SA, Nabbi A, Alshalalfa M, Salman A, Abou-Ouf H, Riabowol K, Bismar TA*. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients. Tumour Biol. 2016 Jan 23 [Epub ahead of print]
Yan J, Ojo D, Kapoor A, Lin X, Pinthus JH, Aziz T, Bismar TA, Wei F, Wong N, De Melo J, Cutz JC, Major P, Wood G, Peng H, Tang D. Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer. Cancer Res. 2016 Jan 21. [Epub ahead of print]
Almami A, Hegazy SA, Nabbi A, Alshalalfa M, Salman A, Abou-Ouf H, Riabowol K, Bismar TA*. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients. Tumour Biol. 2016 Jan 23 [Epub ahead of print]
Yan J, Ojo D, Kapoor A, Lin X, Pinthus JH, Aziz T, Bismar TA, Wei F, Wong N, De Melo J, Cutz JC, Major P, Wood G, Peng H, Tang D. Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer. Cancer Res. 2016 Jan 21. [Epub ahead of print]
Huang KC, Bègin LR, Palanisamy N, Donnelly B, Bismar TA*. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. Urol. Oncol. 2015 Dec 22 [Epub ahead of print]
Abou-Ouf H, Zhao L, Bismar TA*. ERG expression in prostate cancer: biological relevance and clinical
Teng LH, Wang C, Dolph M, Donnelly B, Bismar TA. ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer. JSRN Urol. 2013 Aug 19;2013:786545. doi: 10. 115512013/786545
Mosquera JM, Belltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson J B, Na nus OM, Rubin M A. Concurrent A URKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013 Jan;1 5( I ):1-l 0.
Qabaja A, Alshalalfa M, Bismar TA, A I hajj R. Protein network-based Lasso regression model for the construction of disease-mi RN A functional interactions. EURASIP J Bioinform Syst Bioi. 2013 Jan 22;20 1 3(1):3.
Taherian N, Hamel N, Begin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD. Familial prostate cancer: the damage done and lessons learnt. Nat Rev Ural. 2012 Dec 11;10(2):116-22
Watson K, Wang C, Yi lmaz A, Bismar TA, Trpkov K. Use of immunohistochemistry in routine workup of prostate needle biopsies: A tertiary academic institution experience. Arch Pathol & Lab Medicine 2012 Dec 28.
Alshalalfa M, Bismar TA, A lhajj R. Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks. Adv Bioinformatics. 2012;201 2:373506.
Bismar TA, Dolph M, Teng Ll-1., Li u S, Don nelly B. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. EurJCancer. 2012 Mar;48(4):538-46.
Sircar K, Huang H, Hu L, Cogdell D, Dhillon 1, Tzelepi V, Efstathiou E, Koumakpayi TH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals asparagines synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 2012 Mar;180(3):895-903.
Petersen L, Brockton NT, Bakkar A, Liu S, Wen J, Weljie A, Bismar TA. Elevated physiological levels of folic acid can increase in vitro growth and invasiveness of prostate cancer cells. BJU Int. 2012 Mar;l 09(5):788-95.
Fraser M , Zhao H, Lundi n C, Coackley CL, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: Implications for radiotherapy and chemotherapy. Clin Cancer Res. 201 2 Feb 15;18(4):1015-27.
Yoshimoto M. Ludkovski 0, Degrace D, Williams JL, Evans A, Sircar K, Bismar TA, Nuin P, Squire J A. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer. 2012 Feb;5 1 (2):149-60.
Calderon MR, Yerway M, An BS, Difeo A, Bismar TA, An n OK, Mmtignetti J A, Shalorn Barak T, White J H. Ligand-dependent corepressor (LCoR) recruitment by Druppel-l ike factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN I A Gene. J Bioi Chem. 2012 Mar 16; 287(12):8662-74.
Bismar TA, Yoshimoto M, Duan Q, Liu S, Si rcar K, Squire J A. Interactions and relationships of PTEN. ERG, S PINKJ and AR in castration-resistant prostate cancer. Histopathology 2012 Mar;60(4):645-652.